Wai Chun Bio-Technology Limited (0660) published its 2024/2025 annual report, detailing a year-on-year revenue increase of approximately 1.9% to HK$377.2 million for the year ended 30 June 2025. Gross profit rose from HK$34.2 million in the previous year to HK$36.0 million, while gross profit margin reached 9.5%.

Selling expenses rose by about 13.3% to HK$14.1 million, reflecting higher sales activity. Administrative expenses held relatively steady at around HK$20.8 million, representing a 2.6% increase over the prior year. Impairment losses on non-current assets amounted to approximately HK$1.7 million, markedly lower compared to HK$58.1 million a year ago.

Loss attributable to owners of the Company stood at HK$14.6 million, showing improvement from the HK$44.2 million recorded last year. The Group’s net current liabilities amounted to HK$170.5 million, with a net debt-to-total assets ratio of around 79.9%. The Board has not recommended the payment of any final dividend for the reporting year.

Management emphasized the Group’s efforts in strategic acquisitions and ongoing measures to strengthen revenue fundamentals and cash flows. Capital restructuring proposals and potential fundraising opportunities have also been highlighted, aimed at improving the Group’s operational stability. Meanwhile, no major acquisitions or disposals were recorded during the year, and there was no purchase, sale, or redemption of the Company’s listed securities.

Looking ahead, Wai Chun Bio-Technology Limited (0660) remains focused on enhancing its core manufacturing and sale of modified starch and other biochemical products segments, while continuing cost-management initiatives, maintaining environmental compliance, and ongoing discussion with various parties for possible investment opportunities. The full annual report provides more details on financial performance, corporate governance, and risk management.